[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Middlesex University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100631976","can-astaxanthin-help-manage-asthma-in-polluted-areas-100631976",false,"NCT07507682","Can Astaxanthin Help Manage Asthma in POlluted Areas?","Investigating Astaxanthin as a Novel Therapy for Asthma Management in Polluted Environments","Inclusion Criteria:\n\n* Adults 18+ y\n* Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:\n\n  * A physician diagnosed asthma condition consistent with BTS\u002FNICE\u002FSIGN (2024)\n  * Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment\n  * No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks\n\n(those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical investigations to assess for asthma and thus be included or excluded)\n\n* Ability to demonstrate acceptable and repeatable spirometry in accordance with ATS\u002FERS standards\n* Willing to refrain from antioxidant and anti-inflammatory supplementation (e.g. Omega-3, turmeric, NSAID supplements) for the duration of the study\n* Not consuming high dietary ASTX sources (e.g., frequent salmonid or crustacean intake), assessed at screening\n* non-smoking and non-vaping\n* Able and willing to take daily study capsules and attend all required visits\n* Able and willing to complete home monitoring, including peak flow, air-quality monitoring, and questionnaires\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target interventions\n* Respiratory tract infection within the preceding 4 weeks\n* Pregnant or lactating individuals\n* Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases\n* Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism\n* Known allergy or hypersensitivity to ASTX or any components of the study supplement\n* History of current evidence of alcohol or substance abuse\n* Participation in another interventional drug or supplement study within the preceding 3 months\n* Use of medicines with a narrow therapeutic index where supplement interactions may pose risk (e.g., ciclosporin\u002Ftacrolimus, warfarin), assessed by investigator\n* Other significant chronic respiratory disease (e.g., COPD, bronchiectasis)",true,"ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design. Each treatment period lasts 4 weeks and is separated by a 3-week washout period. The study also measures indoor and personal air pollution exposure to examine whether pollution influences asthma symptoms, airway responsiveness, and response to treatment. Exploratory thoracic bioelectrical impedance spectroscopy will be assessed alongside standard respiratory tests.",[27,28,29],"Asthma (Diagnosis)","Airway Inflammation","Airway Hyperresponsiveness",[31,32,33,34,35,36,37],"Astaxanthin","Mild-to-Moderate Asthma","Air Pollution","FeNO","Hypertonic Saline Challenge","Impulse Oscillometry","Thoracic Bioelectrical Impedance Spectroscopy","RECRUITING","2026-03-27",{"date":41,"type":42},"2026-04-02","ACTUAL",{"date":44,"type":21},"2026-05-15",{"date":46,"type":21},"2026-07-20",{"name":48,"class":49},"Middlesex University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100617909","the-effectiveness-of-a-herbal-supplement-in-osteoarthritis-100617909","NCT07324746","The Effectiveness of a Herbal Supplement in Osteoarthritis.","Effectiveness of a Herbal Supplement Containing Boswellia Serrata, Curcuma Longa, and Vitis Vinifera in Patients With Osteoarthritis.","Inclusion Criteria:\n\n* Aged ≥ 18\n* Diagnosis of osteoarthritis in knee or hip\n* Numerical Rating Scale (NRS) ≥ 4 during the most painful movement in the last 24 hours\n* Lequesne's Functional Index (LFI) score ≥ 7\n* Ambulant patient\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding\n* Autoimmune disease such as rheumatoid arthritis, gout, lupus\n* Joint trauma, joint injury, joint infection, meniscus tear, complete loss of articular cartilage\n* Expectation of surgery\n* History of the viscous or corticosteroids injections into affected joints or oral corticosteroids within last 12 months\n* Allergy to one of the intervention's ingredients or NSAIDs\n* Peptic ulceration and upper gastrointestinal haemorrhage\n* High alcohol intake, inability to abstain from alcohol, substance abuse, history of addiction\n* Tumor, cancer\n* Abnormal renal or\u002Fand hepatic functions or altered blood chemistry\n* Use of concomitant medication able to interfere with the interventions",{"count":59,"type":21},30,[24],"This study aims to evaluate the effectiveness and safety of a combined herbal supplement containing Boswellia serrata, Curcuma longa, and Vitis vinifera in adults with clinically diagnosed knee or hip osteoarthritis.\n\nThe primary objective is to determine whether the supplement improves osteoarthritis-related symptoms.\n\nThe supplement will be compared with a placebo.\n\nParticipants will:\n\n* take the supplement and placebo for 4 weeks each, one at a time;\n* complete validated questionnaires (6 times online)\n* perform three performance-based physical tests (6 times online)\n* provide a urine sample",[63,64,65,66],"Osteoarthritis (OA)","Osteoarthritis (OA) of the Hip","Osteoarthritis (OA) of the Knee","Osteoarthritis",[68,69,70,71,66,72,73,74],"Boswellia serrata","Curcuma longa","Curcumin","Turmeric","Grape extract","Knee osteoarthritis","Hip osteoarthritis","2026-01-27",{"date":77,"type":42},"2026-01-29",{"date":79,"type":42},"2025-12-05",{"date":81,"type":21},"2026-09",{"name":48,"class":49},""]